Rupee at 95, crude at $120+: Why India's markets are flying blind into a storm
Market expert Sudip Bandyopadhyay warns Indian markets face significant risks. High oil prices and a potential monsoon deficit are major concerns. He advises investors to buy stocks slowly and gradually. Large-cap companies and businesses focused ...
India's benchmark indices may look calm on the surface, but veteran market expert Sudip Bandyopadhyay is sounding the alarm: the worst is not priced in, and investors who act on hope rather than data could pay a steep price.
"The situation is far worse than what the market is factoring in. Oil at $120-plus is already destroying the rupee — and the market is simply hoping this conflict ends," says Bandyopadhyay, talking to ET Now.
With the Indian rupee crashing to an all-time low of 95 against the dollar and crude oil holding above $120 per barrel due to the ongoing West Asia conflict, the macro headwinds facing Indian equities are formidable. Add a looming El Niño-driven monsoon deficit predicted by both IMD and Skymet, and the picture becomes even more sobering.
Bandyopadhyay believes markets are being buoyed by two hopes — a swift resolution to the geopolitical conflict, and a sweep by the BJP in upcoming state elections. He cautions that even a favorable election outcome would be "just a feel-good factor" that doesn't move the needle on economic fundamentals.
So what should investors do?
Despite the dark clouds, Bandyopadhyay is not telling investors to sit on the sidelines — at least not if they're playing the long game. His advice: deploy capital in tranches.
"Nobody can identify the bottom. Start slowly buying in. Put 10–20% to work now, wait, then put another 10–20%. Gradually accumulate."
ADVERTISEMENT
For risk-averse investors, he strongly favors large-caps over mid- and small-caps at this juncture, citing lower risk and better visibility during uncertain times. Aggressive investors, he says, can look at beaten-down construction stocks linked to West Asia exposure, while defensive portfolios should rotate into pharma.
In pharma, he's particularly bullish on Sun Pharma following its landmark Organon acquisition, which shifts more than 70% of revenues to branded products — a rarity among Indian pharma majors. He sees no cause for concern over the debt taken on, given the combined free cash flows. For the GLP-1 opportunity, he points to Dr. Reddy's as ahead of peers, with a Canada approval already in hand. Mankind Pharma earns its place for domestic-market insulation.
On the banking side, he likes RBL Bank for its new management and improved balance sheet, and IndusInd Bank for management quality — though he flags that new RBI provisioning norms may create a one-or-two-quarter earnings drag.
Reliance Industries, he says, will break out of its long trading range only when the Jio Platforms IPO materializes — an event he believes is closer than many expect. Green energy clarity and data centre announcements add to the longer-term thesis, while O2C headwinds remain a near-term drag.
ADVERTISEMENT
The bottom line
Oil needs to stabilize between $80–90 a barrel for India's macro story to recover. Until then, the smart money is building positions slowly, sticking to large-caps and domestic-focused businesses, and tuning out the election noise.
